What Is the Most Effective Therapy for Preventing NSAID-Induced Gastropathy?

References

• Lanza F L. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 2037–46
   PubMed Web of Science ®Google Scholar
• Singh G, Rameyu D R, Morfeld D, Shi H, Hatoum H T, Fries J F. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med 1996; 156: 1530–6
   PubMed Web of Science ®Google Scholar
• McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal tox-icity: Definitions and epidemiology. Am J Med 1998; 105: 3S–9S
   PubMedGoogle Scholar
• October 25, 2001, Pharmacia Website. Accessed
   Google Scholar
• Willett L R, Carson J L, Strom B L. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Safety 1994; 10(2)170–81
   PubMedGoogle Scholar
• Hawkins C, Hanks G W. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs. A review of the Literature. J Pain Symptom Manage 2000; 20: 140–51
   PubMed Web of Science ®Google Scholar
• Taha A S, Hudson N, Hawkey C J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996; 334: 1435–9
   PubMed Web of Science ®Google Scholar
• Ten Wolde S, Dijkmans B A, Janssen M, et al. High dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients takings NSAIDs. Alimet Pharmacol Ther 1996; 10: 347–51
   PubMed Web of Science ®Google Scholar
• Hudson N, Taha A S, Russell R I. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug associated gastroduodenal ulceration. Gastroen-terology 1997; 112: 1817–22
   PubMed Web of Science ®Google Scholar
• Dajani E Z, Agrawal N M. Prevention of nonsteroidal anti-inflammatory drug induced gastroduodenal ulcers: Role of mucosal protective and gastric antisecretory drugs. Dig Dis 1995; 13(suppl 1)48–61
   PubMedGoogle Scholar
• Raskin J B, White R H, Jackson J E, et al. Misoprostil dosage in the prevention of nonsteroidal anti-inflammatory drug induced gastric and duodenal ulcers: A comparison of three regastrointestinalmens. Ann Intern Med 1995; 123: 344–50
   PubMed Web of Science ®Google Scholar
• Silverstein F E, Graham D Y, Senior J R, et al. Misoprostil reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9
   PubMed Web of Science ®Google Scholar
• Sontag S. Lansoprazole causes significantly less diarrhea than misoprostil when used to prevent NSAID associated ulcers. Am J Gastroenterol 1999; 94(9)2620
   Google Scholar
• Raskin J B, White R H, Jaszewski R. Misoprostil and ranitidine in the prevention of NSAID induced ulcers: A prospective, double blind multicenter study. Am J Gastroenterol 1996; 91: 223–8
   PubMed Web of Science ®Google Scholar
• Rostom A, Wells G, Tugwell P, et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A cochrane collaboration meta-analysis of randomized controlled trials. J Rheumatol 2000; 27: 2203–14
   PubMed Web of Science ®Google Scholar
• Plosker Gl, Lamb H M. Diclofenac/misoprostil, pharmacoeconomic implications of therapy. Pharmacoeconomics 1999; 16(1)85–98
   PubMedGoogle Scholar
• Hawkey C J, Karrasch J A, Szczepanski L, et al. Omeprazole compared with misoprostil for ulcers associated with nonsteroidal anti-inflammatory agents. N Engl J Med 1998; 338: 727–34
   PubMed Web of Science ®Google Scholar
• Yeomans N D, Tulassay Z T, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719–26
   PubMed Web of Science ®Google Scholar
• Agrawal N M, Campbell D R, Safdi M A, et al. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug associated gastric ulcers. Arch Intern Med 2000; 160: 1455–61
   PubMed Web of Science ®Google Scholar
• Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omperazole in patients receiving continuous anti-inflammatory therapy. Scand J Gastroenterol 1996; 31: 753–8
   PubMed Web of Science ®Google Scholar
• Cullen D, Bardhan K D, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for nonsteroidal antiinflammatory drug users. Aliment Pharmacol Ther 1998; 12(2)135–40
   PubMed Web of Science ®Google Scholar
• Silverstein F E, Faich G, Goldstein J L, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247–55
   PubMed Web of Science ®Google Scholar
• Goldstein J L, Correa P, Zhao W, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019–27
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8
   PubMed Web of Science ®Google Scholar
• Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib, ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The Rofecoxib osteoarthritis en-doscopy multinational study group. Arthritis Rheum 2000; 43: 370–7
   PubMed Web of Science ®Google Scholar
• Acevedo E, Castaneda O, Ugaz M. Tolerability profiles of rofecoxib and Arthrotec. A comparison of six weeks of treatment in patients with osteoarthritis. Scand J Rheumatol 2001; 30(1)19–24
   PubMedGoogle Scholar
• Langman M J, Jensen D M, Watson D J, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929–33
   PubMed Web of Science ®Google Scholar
• Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2 specific inhibitor with that of ibuprofen on the gastro-duodenal mucosa of patients with osteoarthritis. Gastroenterol 1999; 117: 776–83
   PubMed Web of Science ®Google Scholar
• Simon L S, Weaver A L, Graham D Y, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis-a randomized controlled trial. JAMA 1999; 282: 1921–8
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvein T K, et al. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: Randomized double blind comparison. Lancet 1999; 354: 2106–11
   PubMed Web of Science ®Google Scholar
• Celebrex (celecoxib capsules) product information. G.D. Searle, Chicago, IL December, 1998
   Google Scholar
• Vioxx (rofecoxib tablets and oral suspension) product information. Merck & Co., Inc., West Point, PA September, 1999
   Google Scholar
• Polisson R. Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection. Am J Med 1996; 100: 31S–6S
   PubMed Web of Science ®Google Scholar
• Roth S H. NSAID Gastropathy. Arch Intern Med 1996; 156: 1623–8
   PubMedGoogle Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastro-pathy. Am J Med 1998; 105: 31–8S
   PubMedGoogle Scholar
• Wolfe M M, Lichtenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. New Engl J Med 1999; 340: 1888–99
   PubMed Web of Science ®Google Scholar
• Chandramouli J C, Tolman K G. Prevention and management of NSAID induced gastropathy. J Pharm Care Pain Symptom Control 2000; 8(4)27–40
   Google Scholar